SUNDAY, December 8th

Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Relapse after Transplantation - Novel Strategies
Trial: NCIC CTG LY.12
Abstract: 155 A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12
Michael Crump, MD FRCPC, John Kuruvilla, MD, C. Tom Kouroukis, MD, MSc, FRCP(C), Ann Benger, MD, FRCP(C), Matthew C. Cheung, MD, FRCP(C), Neil L Berinstein, MD, Stephen Couban, MD, FRCP(C), Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howson-Jan, MD, Armand Keating, MD, Massimo Federico, MD, David A Macdonald, MD, FRCP(C), Harold J. Olney, MD, Morel Rubinger, MD, Michael Voralia, A. Robert Turner, MD, FRCP(C), Tara Baetz, MD, Annette E Hay, MBChB, Marina Djurfeldt, MSc, Ralph M. Meyer, MD, Bingshu Chen, PhD and Lois Shepherd, MD.

Time: 6:00 PM
Location: Riverside Rooms - R06-R07 (Ernest N. Morial Convention Center)
Link: https://ash.confex.com/ash/2013/webprogram/Paper60435.html

Program: Oral and Poster Abstracts
Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
Trial: NCIC CTG HD.7 (ECOG 2496)
Abstract: 3060 The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience
Fangxin Hong, PhD, Thomas M Habermann, MD, Leo I. Gordon, MD, Howard S Hochster, MD, Randy D. Gascoyne, MD, Vicki A. Morrison, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Patrick J Stiff, MD, Bruce D. Cheson, MD, Michael Crump, MD FRCP(C), Sandra J. Horning, MD and Brad S. Kahl, MD.

Time: 6:30 PM-8:30 PM
Location: Hall G (Ernest N. Morial Convention Center)
Link: https://ash.confex.com/ash/2013/webprogram/Paper63545.html
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Antibody-Based Targeted Therapy
Trial: NCIC CTG ALC.1 (SWOG 0106)
Abstract: The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials
Robert K. Hills, MA, MSc, DPhil, Stephen Petersdorf, MD, Elihu H. Estey, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Sylvie Castaigne, Herve Dombret, MD, PhD, Sylvie Chevret, Jacques Delaunay, MD, Norbert Ifrah, Jean-Yves Cahn, MD, PhD, Christian Recher, MD and Alan K Burnett, MD.
Time: 10:45 AM
Location: La Nouvelle Ballroom C (Ernest N. Morial Convention Center)
Link: https://ash.confex.com/ash/2013/webprogram/Paper61280.html

Program: Oral and Poster Abstracts
Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster III
Trial: NCIC CTG HD.7 (ECOG 2496)
Abstract: Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496
Catherine S. Diefenbach, MD, Hailun Li, MS, Fangxin Hong, PhD, Leo I. Gordon, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Michael Crump, MD FRCPC, Randy D. Gascoyne, MD, Henry Wagner Jr., MD, Patrick J Stiff, MD, Bruce D. Cheson, MD, Douglas A. Stewart, MD, FRCPC, Brad S. Kahl, MD, Jonathan W. Friedberg, MD, Kristie A. Blum, MD, Thomas M. Habermann, MD, Joseph Tuscano, MD, Richard T. Hoppe, MD, Sandra J. Horning, MD and Ranjana H. Advani, MD.
Time: 6:00 PM-8:00 PM
Location: Hall G (Ernest N. Morial Convention Center)
Link: https://ash.confex.com/ash/2013/webprogram/Paper60152.html